MBP and myeloid sarcoma: A phase 1b trial of intradermal apitopes from MBP in relapsing-MS [52•], reported a significant (p = 0.03) reduction in gadolinium-enhancing lesions while a phase 2 study revealed a marked improvement in cognition that correlated with suppression of CNS inflammation [18••].